Next-gen RNAi drugmaker City prices $200M IPO

T2Covered by 1 source · first reported by BioPharma Dive / Healthcare Dive / MedTech Dive at 16 Oct, 10:33 UTC

The offering will support a trio of medicines in or nearing clinical testing, as well as earlier research into RNAi treatments that get into tissues outside the liver.

businessscience

Sources

• T2Next-gen RNAi drugmaker City prices $200M IPOBioPharma Dive / Healthcare Dive / MedTech Dive16 Oct, 10:33